1. Home
  2. YSG vs TENX Comparison

YSG vs TENX Comparison

Compare YSG & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSG

Yatsen Holding Limited

HOLD

Current Price

$3.43

Market Cap

292.7M

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$15.09

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
TENX
Founded
2016
1967
Country
China
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
292.7M
317.8M
IPO Year
2020
2001

Fundamental Metrics

Financial Performance
Metric
YSG
TENX
Price
$3.43
$15.09
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
169.4K
1.3M
Earning Date
05-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.08
N/A
Revenue Next Year
$9.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$5.73
52 Week High
$11.04
$18.38

Technical Indicators

Market Signals
Indicator
YSG
TENX
Relative Strength Index (RSI) 58.07 68.00
Support Level $2.78 $12.84
Resistance Level $3.71 $16.35
Average True Range (ATR) 0.28 0.98
MACD 0.01 0.36
Stochastic Oscillator 83.05 99.31

Price Performance

Historical Comparison
YSG
TENX

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: